| Peer-Reviewed

Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review

Received: 28 November 2021     Accepted: 15 December 2021     Published: 29 December 2021
Views:       Downloads:
Abstract

Glycogen storage disease type Ia is a genetic disease caused by glucose-6-phosphatase deficiency, which often causes hypoglycemia, hyperuricemia, hypertriglyceridemia, and lactic acidemia. Severe lactic acidosis is a serious complication of glycogen storage disease type Ia. This study aimed to analyze the clinical features and treatment of glycogen storage disease type Ia with severe lactic acidosis. We performed a retrospective analysis of the diagnosis and treatment of a patient with glycogen storage disease type Ia with severe lactic acidosis admitted to our department during the COVID-19 period and reviewed the related literature. The patient was admitted to our hospital for chest pain and vomiting of three days duration, which was accompanied by dyspnea for five hours. The patient has had a type Ia glycogen storage disease for 11 years, and arterial blood gas analysis revealed a pH of 7.192 and lactic acid levels of 26.77 mmol/L. However, the patient was diagnosed with type Ia glycogen storage disease alongside severe lactic acidosis. After 4 hours of hemodialysis and 36 hours of continuous blood purification, the patient had no shortness of breath, dyspnea, nausea, or vomiting. Biochemical retesting indicated a pH of 7.482, lactic acid levels of 7.41 mmol/L, and blood glucose levels of 10.7 mmol/L. Glycogen storage disease type Ia can lead to life-threatening severe lactic acidosis. Continuous renal replacement therapy is an effective treatment for severe lactic acidosis. Therefore, as prevention and control are being carried out during the COVID-19 period, attention should be given to the treatment of special populations, such as those with glycogen storage disease to prevent serious complications.

Published in American Journal of Pediatrics (Volume 7, Issue 4)
DOI 10.11648/j.ajp.20210704.19
Page(s) 229-233
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Glycogen Storage Disease, Lactic Acidosis, Continuous Renal Replacement Therapy

References
[1] Chou, J. Y., Jun, H. S., & Mansfield, B. C. (2010). Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nature reviews. Endocrinology, 6 (12), 676–688. https://doi.org/10.1038/nrendo.2010.189.
[2] Chou, J. Y., Matern, D., Mansfield, B. C., & Chen, Y. T. (2002). Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Current molecular medicine, 2 (2), 121–143. https://doi.org/10.2174/1566524024605798.
[3] Wolfsdorf, J. I., & Weinstein, D. A. (2003). Glycogen storage diseases. Reviews in endocrine & metabolic disorders, 4 (1), 95–102. https://doi.org/10.1023/a:1021831621210.
[4] Rake, J. P., Visser, G., Labrune, P., Leonard, J. V., Ullrich, K., Smit, G. P., & European Study on Glycogen Storage Disease Type I (ESGSD I) (2002). Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). European journal of pediatrics, 161 Suppl 1, S112–S119. https://doi.org/10.1007/s00431-002-1016-7.
[5] Kishnani, P. S., Austin, S. L., Abdenur, J. E., Arn, P., Bali, D. S., Boney, A., Chung, W. K., Dagli, A. I., Dale, D., Koeberl, D., Somers, M. J., Wechsler, S. B., Weinstein, D. A., Wolfsdorf, J. I., Watson, M. S., & American College of Medical Genetics and Genomics (2014). Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genetics in medicine: official journal of the American College of Medical Genetics, 16 (11), e1. https://doi.org/10.1038/gim.2014.128.
[6] Nichol, A. D., Egi, M., Pettila, V., Bellomo, R., French, C., Hart, G., Davies, A., Stachowski, E., Reade, M. C., Bailey, M., & Cooper, D. J. (2010). Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. Critical care (London, England), 14 (1), R25. https://doi.org/10.1186/cc8888.
[7] Kraut, J. A., & Madias, N. E. (2014). Lactic acidosis. The New England journal of medicine, 371 (24), 2309–2319. https://doi.org/10.1056/NEJMra1309483.
[8] Huang Haiyan, Zhang Minjie, Yin Yuliang, Zheng Xinglong & Zhang Lilion. (2021). Removal of blood lactic acid by blood purification versus by conventional treatment in lactic acidosis patients: a meta analysis (China Blood Purification (01), 19-23. Doi: CNKI: Sun: zgjh.0.2021-01-005.
[9] Sık, G., Demirbuga, A., Günhar, S., Nisli, K., & Citak, A. (2019). Clinical Features and Indications Associated with Mortality in Continuous Renal Replacement Therapy for Pediatric Patients. Indian journal of pediatrics, 86 (4), 360–364. https://doi.org/10.1007/s12098-019-02868-w.
[10] Parikh, N. S., & Ahlawat, R. (2021). Glycogen Storage Disease Type I. In StatPearls. StatPearls Publishing.
[11] Froissart, R., Piraud, M., Boudjemline, A. M., Vianey-Saban, C., Petit, F., Hubert-Buron, A., Eberschweiler, P. T., Gajdos, V., & Labrune, P. (2011). Glucose-6-phosphatase deficiency. Orphanet journal of rare diseases, 6, 27. https://doi.org/10.1186/1750-1172-6-27.
[12] Chou, J. Y., Jun, H. S., & Mansfield, B. C. (2015). Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. Journal of inherited metabolic disease, 38 (3), 511–519. https://doi.org/10.1007/s10545-014-9772-x.
[13] Santos, B. L., Souza, C. F., Schuler-Faccini, L., Refosco, L., Epifanio, M., Nalin, T., Vieira, S. M., & Schwartz, I. V. (2014). Glycogen storage disease type I: clinical and laboratory profile. Jornal de pediatria, 90 (6), 572–579. https://doi.org/10.1016/j.jped.2014.02.00.
[14] Steunenberg, T., Peeks, F., Hoogeveen, I. J., Mitchell, J. J., Mundy, H., de Boer, F., Lubout, C., de Souza, C. F., Weinstein, D. A., & Derks, T. (2018). Safety issues associated with dietary management in patients with hepatic glycogen storage disease. Molecular genetics and metabolism, 125 (1-2), 79–85. https://doi.org/10.1016/j.ymgme.2018.07.004.
[15] Fall, P. J., & Szerlip, H. M. (2005). Lactic acidosis: from sour milk to septic shock. Journal of intensive care medicine, 20 (5), 255–271. https://doi.org/10.1177/0885066605278644.
[16] Kraut, J. A., & Kurtz, I. (2001). Use of base in the treatment of severe acidemic states. American journal of kidney diseases: the official journal of the National Kidney Foundation, 38 (4), 703–727. https://doi.org/10.1053/ajkd.2001.27688.
[17] Karkar A. (2019). Continuous renal replacement therapy: Principles, modalities, and prescription. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 30 (6), 1201–1209. https://doi.org/10.4103/1319-2442.275463.
[18] Liu, Y., Ouyang, B., Chen, J., Chen, M., Ma, J., Wu, J., Huang, S., Li, L., Liu, Z., & Guan, X. (2014). Effects of different doses in continuous veno-venous hemofiltration on plasma lactate in critically ill patients. Chinese medical journal, 127 (10), 1827–1832.
[19] Song Yan, Li Wei, Zhang Yong, Jing Danqing, Chen Yuxi, Gong Ping. (2002). Comparison of continuous renal replacement therapy and regular hemodialysis in severe lactic acidosis therapy. Chinese blood purification (06), DOI: CNKI: Sun: zgjh. 0.2002-06-002.
[20] Kruse, O., Grunnet, N., & Barfod, C. (2011). Blood lactate as a predictor for in-hospital mortality in patients admitted acutely to hospital: a systematic review. Scandinavian journal of trauma, resuscitation and emergency medicine, 19, 74. https://doi.org/10.1186/1757-7241-19-74.
[21] Oster, Y., Wexler, I. D., Heyman, S. N., & Fried, E. (2016). Recoverable, Record-High Lactic Acidosis in a Patient with Glycogen Storage Disease Type 1: A Mixed Type A and Type B Lactate Disorder. Case reports in medicine, 2016, 4362743. https://doi.org/10.1155/2016/4362743.
Cite This Article
  • APA Style

    Yu Luo, Fang Yang, Ding Liu, Zhiqiang Guo, Chongfeng Chen. (2021). Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review. American Journal of Pediatrics, 7(4), 229-233. https://doi.org/10.11648/j.ajp.20210704.19

    Copy | Download

    ACS Style

    Yu Luo; Fang Yang; Ding Liu; Zhiqiang Guo; Chongfeng Chen. Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review. Am. J. Pediatr. 2021, 7(4), 229-233. doi: 10.11648/j.ajp.20210704.19

    Copy | Download

    AMA Style

    Yu Luo, Fang Yang, Ding Liu, Zhiqiang Guo, Chongfeng Chen. Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review. Am J Pediatr. 2021;7(4):229-233. doi: 10.11648/j.ajp.20210704.19

    Copy | Download

  • @article{10.11648/j.ajp.20210704.19,
      author = {Yu Luo and Fang Yang and Ding Liu and Zhiqiang Guo and Chongfeng Chen},
      title = {Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review},
      journal = {American Journal of Pediatrics},
      volume = {7},
      number = {4},
      pages = {229-233},
      doi = {10.11648/j.ajp.20210704.19},
      url = {https://doi.org/10.11648/j.ajp.20210704.19},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20210704.19},
      abstract = {Glycogen storage disease type Ia is a genetic disease caused by glucose-6-phosphatase deficiency, which often causes hypoglycemia, hyperuricemia, hypertriglyceridemia, and lactic acidemia. Severe lactic acidosis is a serious complication of glycogen storage disease type Ia. This study aimed to analyze the clinical features and treatment of glycogen storage disease type Ia with severe lactic acidosis. We performed a retrospective analysis of the diagnosis and treatment of a patient with glycogen storage disease type Ia with severe lactic acidosis admitted to our department during the COVID-19 period and reviewed the related literature. The patient was admitted to our hospital for chest pain and vomiting of three days duration, which was accompanied by dyspnea for five hours. The patient has had a type Ia glycogen storage disease for 11 years, and arterial blood gas analysis revealed a pH of 7.192 and lactic acid levels of 26.77 mmol/L. However, the patient was diagnosed with type Ia glycogen storage disease alongside severe lactic acidosis. After 4 hours of hemodialysis and 36 hours of continuous blood purification, the patient had no shortness of breath, dyspnea, nausea, or vomiting. Biochemical retesting indicated a pH of 7.482, lactic acid levels of 7.41 mmol/L, and blood glucose levels of 10.7 mmol/L. Glycogen storage disease type Ia can lead to life-threatening severe lactic acidosis. Continuous renal replacement therapy is an effective treatment for severe lactic acidosis. Therefore, as prevention and control are being carried out during the COVID-19 period, attention should be given to the treatment of special populations, such as those with glycogen storage disease to prevent serious complications.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Blood Purification Technology in the Treatment of Type Ia Glycogen Storage Disease Complicated with Severe Lactic Acidosis: A Case Report and Literature Review
    AU  - Yu Luo
    AU  - Fang Yang
    AU  - Ding Liu
    AU  - Zhiqiang Guo
    AU  - Chongfeng Chen
    Y1  - 2021/12/29
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ajp.20210704.19
    DO  - 10.11648/j.ajp.20210704.19
    T2  - American Journal of Pediatrics
    JF  - American Journal of Pediatrics
    JO  - American Journal of Pediatrics
    SP  - 229
    EP  - 233
    PB  - Science Publishing Group
    SN  - 2472-0909
    UR  - https://doi.org/10.11648/j.ajp.20210704.19
    AB  - Glycogen storage disease type Ia is a genetic disease caused by glucose-6-phosphatase deficiency, which often causes hypoglycemia, hyperuricemia, hypertriglyceridemia, and lactic acidemia. Severe lactic acidosis is a serious complication of glycogen storage disease type Ia. This study aimed to analyze the clinical features and treatment of glycogen storage disease type Ia with severe lactic acidosis. We performed a retrospective analysis of the diagnosis and treatment of a patient with glycogen storage disease type Ia with severe lactic acidosis admitted to our department during the COVID-19 period and reviewed the related literature. The patient was admitted to our hospital for chest pain and vomiting of three days duration, which was accompanied by dyspnea for five hours. The patient has had a type Ia glycogen storage disease for 11 years, and arterial blood gas analysis revealed a pH of 7.192 and lactic acid levels of 26.77 mmol/L. However, the patient was diagnosed with type Ia glycogen storage disease alongside severe lactic acidosis. After 4 hours of hemodialysis and 36 hours of continuous blood purification, the patient had no shortness of breath, dyspnea, nausea, or vomiting. Biochemical retesting indicated a pH of 7.482, lactic acid levels of 7.41 mmol/L, and blood glucose levels of 10.7 mmol/L. Glycogen storage disease type Ia can lead to life-threatening severe lactic acidosis. Continuous renal replacement therapy is an effective treatment for severe lactic acidosis. Therefore, as prevention and control are being carried out during the COVID-19 period, attention should be given to the treatment of special populations, such as those with glycogen storage disease to prevent serious complications.
    VL  - 7
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Pediatrics, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Pediatrics, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Pediatrics, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Pediatrics, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Pediatrics, The First Affiliated Hospital of Jinan University, Guangzhou, China

  • Sections